BioSpace News Archive

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced today that it has successfully developed a rapid quantitative tear test for Lacritin, a tear protein that autonomously promotes tearing and is deficient in all forms of Dry Eye Disease.

Amgen (NASDAQ:AMGN) today announced top-line results from two Repatha® (evolocumab) open label extension (OLE) studies to the Phase 3 FOURIER cardiovascular outcomes trial.

For the first time ever, adults can opt for a clean alternative with the same efficacy as its counterparts in the medicine aisles.

Yield10 Bioscience, Inc., an agricultural bioscience company, named Willie Loh, Ph.D., as a special advisor to the Board of Directors and Management of the Company, effective immediately.

Tempest Therapeutics, Inc. announced that two abstracts were accepted for presentation at the 2022 American Society of Clinical Oncology Annual Meeting taking place June 3-7, 2022 at the McCormick Place Convention Center in Chicago, IL.

Elevation Oncology, Inc. (Nasdaq: ELEV), today announced that its abstract highlighting initial data from patients in Cohort 1 of the ongoing Phase 2 CRESTONE study was selected for oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 3-7, 2022 in Chicago.

Coya Therapeutics, Inc. (“Coya”), a privately held clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced the publication of results from a Phase 1 trial entitled “Tregs Attenuate Peripheral Oxidative Stress and Acute Phase Proteins in ALS.”

Aether Biomachines, a nanotechnology company building a future of abundance, announced the appointment of True North Venture Partners’ Erik Scher, Ph.D., to its Board of Directors.

PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their latest research results were presented at the World Vaccine Congress on April 20.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the acceptance of an abstract for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting.